Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
40
BBWI Quote, Financials, Valuation and Earnings
Last price:
$29.87
Seasonality move
:
6.59%
Day range:
$30.27 - $30.94
52-week range:
$24.96 - $52.99
Dividend yield:
2.64%
P/E ratio:
8.33x
P/S ratio:
0.92x
P/B ratio:
--
Volume:
3.3M
Avg. volume:
5.5M
1-year change:
-34.04%
Market cap:
$6.5B
Revenue:
$7.3B
EPS (TTM):
$3.64
Analysts' Opinion
-
Consensus RatingBath & Body Works has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $44.25, Bath & Body Works has an estimated upside of 45.93% from its current price of $30.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $30.32.
Fair Value
-
According to the consensus of 14 analysts, Bath & Body Works has 45.93% upside to fair value with a price target of $44.25 per share.
BBWI vs. S&P 500
-
Over the past 5 trading days, Bath & Body Works has underperformed the S&P 500 by -4.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bath & Body Works does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bath & Body Works revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bath & Body Works reported revenues of $2.8B.
Earnings Growth
-
Bath & Body Works earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bath & Body Works reported earnings per share of $2.09.
Enterprise value:
9.7B
EV / Invested capital:
--
Price / LTM sales:
0.92x
EV / EBIT:
7.25x
EV / Revenue:
1.33x
PEG ratio (5yr expected):
0.31x
EV / Free cash flow:
14.71x
Price / Operating cash flow:
10.14x
Enterprise value / EBITDA:
5.99x
Gross Profit (TTM):
$3.2B
Return On Assets:
15.65%
Net Income Margin (TTM):
10.92%
Return On Equity:
--
Return On Invested Capital:
31.19%
Operating Margin:
24.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $7.6B | $7.4B | $7.3B | $2.9B | $2.8B | |
| Gross Profit | $3.3B | $3.2B | $3.2B | $1.3B | $1.3B | |
| Operating Income | $1.4B | $1.3B | $1.3B | $696M | $678M | |
| EBITDA | $1.6B | $1.6B | $1.6B | $779M | $758M | |
| Diluted EPS | $3.45 | $3.85 | $3.64 | $2.55 | $2.09 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.6B | $3B | $2.3B | $2.1B | $1.8B | |
| Total Assets | $11.6B | $6B | $5.5B | $5.5B | $4.9B | |
| Current Liabilities | $2.8B | $1.3B | $1.4B | $1.3B | $1.2B | |
| Total Liabilities | $12.2B | $7.5B | $7.7B | $7.1B | $6.3B | |
| Total Equity | -$661M | -$1.5B | -$2.2B | -$1.6B | -$1.4B | |
| Total Debt | $6.4B | $4.9B | $4.9B | $4.4B | $3.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.1B | $954M | $886M | $926M | $955M | |
| Cash From Investing | -$328M | -$286M | -$162M | -$47M | -$48M | |
| Cash From Financing | -$1.6B | -$815M | -$1.1B | -$206M | -$422M | |
| Free Cash Flow | $816M | $656M | $660M | $878M | $895M | |
BBWI
Sector
Market Cap
$6.5B
$397M
Price % of 52-Week High
57.22%
66.9%
Dividend Yield
2.64%
0%
Shareholder Yield
8.56%
4.03%
1-Year Price Total Return
-34.04%
-16.98%
Beta (5-Year)
1.870
0.786
Dividend yield:
2.64%
Annualized payout:
$0.80
Payout ratio:
22.18%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$30.43
200-day SMA
Sell
Level
$33.21
Bollinger Bands (100)
Sell
Level
30.2 - 38.6
Chaikin Money Flow
Buy
Level
342.4M
20-day SMA
Buy
Level
$28.89
Relative Strength Index (RSI14)
Buy
Level
51.59
ADX Line
Buy
Level
19.83
Williams %R
Neutral
Level
-26.9058
50-day SMA
Sell
Level
$31.13
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Sell
Level
-223.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8812)
Sell
CA Score
(Annual)
Level (-2.3741)
Buy
Beneish M-Score
(Annual)
Level (-2.6654)
Sell
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.9258)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store reformatting, digital and international channels, as well as adjacent category expansions like hair and laundry.
Stock Forecast FAQ
In the current month, BBWI has received 10 Buy ratings 4 Hold ratings, and 0 Sell ratings. The BBWI average analyst price target in the past 3 months is $44.25.
-
Where Will Bath & Body Works Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bath & Body Works share price will rise to $44.25 per share over the next 12 months.
-
What Do Analysts Say About Bath & Body Works?
Analysts are divided on their view about Bath & Body Works share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bath & Body Works is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Bath & Body Works's Price Target?
The price target for Bath & Body Works over the next 1-year time period is forecast to be $44.25 according to 14 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is BBWI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bath & Body Works is a Buy. 10 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BBWI?
You can purchase shares of Bath & Body Works via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bath & Body Works shares.
-
What Is The Bath & Body Works Share Price Today?
Bath & Body Works was last trading at $29.87 per share. This represents the most recent stock quote for Bath & Body Works. Yesterday, Bath & Body Works closed at $30.32 per share.
-
How To Buy Bath & Body Works Stock Online?
In order to purchase Bath & Body Works stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
